Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00039507
Status:
COMPLETED
Last Update Posted:
2010-02-12
First Post:
2002-06-06
Brief Title:
Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer
Sponsor:
Fox Chase Cancer Center
Organization:
Fox Chase Cancer Center
Study Overview
Official Title:
Pilot Study Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Radiofrequency ablation uses high-frequency electric current to kill tumor cells Combining radiofrequency ablation with surgery may kill more tumor cells
PURPOSE Phase II trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage I or stage II non-small cell lung cancer
PURPOSE Phase II trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage I or stage II non-small cell lung cancer
Detailed Description:
OBJECTIVES
Determine the acute effects of intraoperative radiofrequency tumor ablation RFA in patients with resectable non-small cell lung cancer
Determine the treatment-related toxicity in patients treated with this therapy
Determine the dimensions of the RFA lesion produced by the ablation procedure in these patients
OUTLINE Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes for each tumor immediately followed by tumor resection
PROJECTED ACCRUAL A maximum of 20 patients will be accrued for this study
Determine the acute effects of intraoperative radiofrequency tumor ablation RFA in patients with resectable non-small cell lung cancer
Determine the treatment-related toxicity in patients treated with this therapy
Determine the dimensions of the RFA lesion produced by the ablation procedure in these patients
OUTLINE Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes for each tumor immediately followed by tumor resection
PROJECTED ACCRUAL A maximum of 20 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G02-2079 | US NIH GrantContract | None | httpsreporternihgovquickSearchP30CA006927 |
| FCCC-02007 | None | None | None |
| P30CA006927 | NIH | None | None |